KRAS-targeting pancreatic cancer drug signals new era in lethal disease
TL;DR Summary
A landmark trial of the KRAS-targeting pill daraxonrasib shows pancreatic cancer patients living about twice as long as with standard chemotherapy and with tumors kept in check longer, a potential breakthrough developed by Revolution Medicines that has prompted FDA expanded access while a full review continues.
Topics:top-news#cancer#clinical-trials#diagnosis-and-treatment#health#medical-research#united-states-nation
- ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long The Washington Post
- After new drug’s ‘unprecedented’ results for pancreatic cancer, doctors look at other uses NBC News
- New drug nearly doubles survival rates in some pancreatic cancer patients, study says CBS News
- Daily pill can double survival time for world’s deadliest cancer, trial shows The Guardian
- ASCO: RevMed confident in Ras leadership as rivals square up Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
28
Time Saved
19 min
vs 20 min read
Condensed
99%
3,883 → 46 words
Want the full story? Read the original article
Read on The Washington Post